https://www.whitehouse.gov/wp-content/uploads/2021/05/budget_fy22.pdf
Tiziana Life Sciences Announces Additional Clinical Improvements In The Second Patient With Non-Active Secondary Progressive Multiple Sclerosis After Eleven Months Of Dosing With Intranasal Foralumab
Tiziana Life Sciences Ltd. (NASDAQ:TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today
